Cancer multidrug resistance (MDR) is a major cause of therapeutic failure in cancer. MDR is mainly due to the overexpression of drug efflux pumps, such as P-glycoprotein (P-gp). Besides overexpression of drug efflux pumps, other molecular mechanisms are involved in the MDR phenotype, including metabolic alterations. Indeed, recent studies showed that it is possible to revert the MDR phenotype by inhibition of glycolysis with specific modulators.
